{
  "id": 20783867,
  "title": "The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters",
  "url": "https://urgent.news/2026/11/19/the-glp-1-blind-spot-why-the-fdas-new-eye-stroke-warning-matters",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T17:30:00.000Z",
  "source": {
    "name": "The Hill",
    "slug": "the-hill",
    "url": "https://thehill.com/opinion/healthcare/6228352-fda-glp1-blinding-warning/"
  },
  "original_language": "en",
  "account": null,
  "summary": "It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}